Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

ver descrição completa

Na minha lista:

Detalhes bibliográficos
Main Authors:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Formato:	Artigo
Idioma:	Inglês
Publicado em:	2011
Acesso em linha:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados

Predicting the outcome of ankylosing spondylitis therapy
Por: Vastesaeger, Nathan, et al.
Publicado em: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
Por: Bert Vander Cruyssen, et al.
Publicado em: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Por: van der Heijde, Désirée, et al.
Publicado em: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Por: Désirée van der Heijde, et al.
Publicado em: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Por: Braun, Jürgen, et al.
Publicado em: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
Por: Jürgen Braun, et al.
Publicado em: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
Por: Wagner, Carrie, et al.
Publicado em: (2011)

Ankylosing spondylitis: an overview
Por: Joachim Sieper, et al.
Publicado em: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Por: Deodhar, Atul, et al.
Publicado em: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Por: Atul Deodhar, et al.
Publicado em: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
Por: Braun, J, et al.
Publicado em: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Por: Désirée van der Heijde, et al.
Publicado em: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Por: Dominique Baeten, et al.
Publicado em: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
Por: Jürgen Braun, et al.
Publicado em: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Por: Jürgen Braun, et al.
Publicado em: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
Por: Jürgen Braun, et al.
Publicado em: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
Por: Inman, Robert D., et al.
Publicado em: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
Por: Xenofon Baraliakos, et al.
Publicado em: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Por: Braun, Jürgen, et al.
Publicado em: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Por: Jürgen Braun, et al.
Publicado em: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
Por: Cruyssen, Bert Vander, et al.
Publicado em: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
Por: Bert Vander Cruyssen, et al.
Publicado em: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
Por: Annelies Boonen, et al.
Publicado em: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Por: Braun, Jürgen, et al.
Publicado em: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
Por: Sambrook, Philip N., et al.
Publicado em: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
Por: Philip N. Sambrook, et al.
Publicado em: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Por: Braun, Jürgen, et al.
Publicado em: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
Por: Zochling, J, et al.
Publicado em: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Por: Désirée van der Heijde, et al.
Publicado em: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
Por: Ben A. C. Dijkmans, et al.
Publicado em: (2009)

Ankylosing spondylitis: an overview
Por: Sieper, J, et al.
Publicado em: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
Por: Sudha Visvanathan, et al.
Publicado em: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Por: Braun, J, et al.
Publicado em: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
Por: Jürgen Braun, et al.
Publicado em: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
Por: Davis, J C, et al.
Publicado em: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
Por: Désirée van der Heijde, et al.
Publicado em: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
Por: Braun, J, et al.
Publicado em: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
Por: Désirée van der Heijde, et al.
Publicado em: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
Por: Vosse, D, et al.
Publicado em: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Por: Jürgen Braun, et al.
Publicado em: (2016)